Last reviewed · How we verify
Usual DMT continuation
DMT acts as a potent agonist at the serotonin 5-HT2A receptor.
DMT acts as a potent agonist at the serotonin 5-HT2A receptor. Used for Treatment-resistant depression.
At a glance
| Generic name | Usual DMT continuation |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Drug class | Serotonin receptor agonist |
| Target | 5-HT2A |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
DMT's mechanism of action primarily involves the activation of the 5-HT2A receptor, which is a subtype of the serotonin receptor. This activation can lead to altered perception, mood changes, and other psychoactive effects. The exact mechanisms underlying DMT's therapeutic effects in the context of Usual DMT continuation are not well understood.
Approved indications
- Treatment-resistant depression
Common side effects
- Hallucinations
- Anxiety
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Usual DMT continuation CI brief — competitive landscape report
- Usual DMT continuation updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI